Date: 2015-12-09
Type of information: Nomination
Compound:
Company: Tiziana Life Sciences (UK)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details: * On December 9, 2015, Tiziana Life Sciences announced today the addition of James Tripp, as Chief Operating Officer (COO) and Head of Global Clinical Operations. Mr. Tripp, who will be responsible for all operations, including global clinical development for the Company, is not being appointed to the plc board. Mr. Tripp has over twenty years’ experience in biopharmaceutical operations and has been involved in all phases of drug development from discovery through commercialization. He started his career in pharmaceuticals while attending Harvard School of Public Health and at Massachusetts General Hospital in Boston, MA. Before joining the Company he was Director, Clinical Management at Novo Nordisk, A/S, where he managed the US team overseeing the oral insulin/GLP-1 portfolio, expanding the Victozaâ label, and completing confirmatory studies required for Saxendaâ which was recently approved to treat obese patients. Prior to Novo Nordisk, Mr. Tripp was employed at Regeneron Pharmaceuticals where he started as a Therapeutic Area Project Manager for inflammation programs, focusing on developing IL-1 Trap (now Arcalyst®) and then creating and heading up the Clinical Compliance & Training group for the Clinical & Project Management Office.
Financial terms:
Latest news:
